/[corp_html]/html/Pipeline.htm
This is repository of my old source code which isn't updated any more. Go to git.rot13.org for current projects!
ViewVC logotype

Diff of /html/Pipeline.htm

Parent Directory Parent Directory | Revision Log Revision Log | View Patch Patch

revision 1.2 by dpavlin, Mon Mar 12 20:06:04 2001 UTC revision 1.3 by dpavlin, Wed Mar 28 19:30:39 2001 UTC
# Line 1  Line 1 
1    
2  <p align="left"><font size="4" color="#FF9933"><b><img src="t/development.gif" width="225" height="16"></b></font></p>  <p align="left"><font size="4" color="#FF9933"><b><img src="t/development.gif" width="225" height="16"></b></font></p>
3  <table width="90%" border="0" cellspacing="0" cellpadding="0" align="center">  <table width="90%" border="0" cellspacing="0" cellpadding="0" align="center">
4    <tr>    <tr>
5      <td height="10" width="19%">      <td height="10" width="19%">
6        <div align="center"><b>PROJECT</b></div>        <div align="center"><b>PROJECT</b></div>
7      </td>      </td>
8      <td height="10" width="26%">      <td height="10" width="26%">
9        <div align="center"><b>INDICATION</b></div>        <div align="center"><b>INDICATION</b></div>
10      </td>      </td>
11      <td height="10" width="24%">      <td height="10" width="24%">
12        <div align="center"><b>STATUS</b></div>        <div align="center"><b>STATUS</b></div>
13      </td>      </td>
14    </tr>    </tr>
15  </table>  </table>
16  <table width="90%" border="1" cellspacing="0" cellpadding="0" align="center">  <table width="90%" border="1" cellspacing="0" cellpadding="0" align="center">
17    <tr>    <tr>
18      <td width="19%">      <td width="19%">
19        <div align="center">PLD - 116</div>        <div align="center">PLD - 116</div>
20      </td>      </td>
21      <td width="26%">      <td width="26%">
22        <div align="center">Inflammatory Bowel Disease (IBD)</div>        <div align="center">Inflammatory Bowel Disease (IBD)</div>
23      </td>      </td>
24      <td width="24%">      <td width="24%">
25        <div align="center">Clinical Trials</div>        <div align="center">Clinical Trials</div>
26      </td>      </td>
27    </tr>    </tr>
28    <tr>    <tr>
29      <td width="19%">      <td width="19%">
30        <div align="center">PLD - 117</div>        <div align="center">PLD - 117</div>
31      </td>      </td>
32      <td width="26%">      <td width="26%">
33        <div align="center">Oncology<br>        <div align="center">Oncology<br>
34          Hematology</div>          Hematology</div>
35      </td>      </td>
36      <td width="24%">      <td width="24%">
37        <div align="center">Clinical Trials</div>        <div align="center">Clinical Trials</div>
38      </td>      </td>
39    </tr>    </tr>
40    <tr>    <tr>
41      <td width="19%">      <td width="19%">
42        <div align="center">PLD - 118</div>        <div align="center">PLD - 118</div>
43      </td>      </td>
44      <td width="26%">      <td width="26%">
45        <div align="center">Anti-fungal</div>        <div align="center">Anti-fungal</div>
46      </td>      </td>
47      <td width="24%">      <td width="24%">
48        <div align="center">Clinical Trials</div>        <div align="center">Clinical Trials</div>
49      </td>      </td>
50    </tr>    </tr>
51    <tr>    <tr>
52      <td width="19%">      <td width="19%">
53        <div align="center">PLR - 1</div>        <div align="center">PLR - 1</div>
54      </td>      </td>
55      <td width="26%">      <td width="26%">
56        <div align="center">Anti-infective</div>        <div align="center">Anti-infective</div>
57      </td>      </td>
58      <td width="24%">      <td width="24%">
59        <div align="center">Discovery</div>        <div align="center">Discovery</div>
60      </td>      </td>
61    </tr>    </tr>
62    <tr>    <tr>
63      <td width="19%">      <td width="19%">
64        <div align="center">PLR - 13</div>        <div align="center">PLR - 13</div>
65      </td>      </td>
66      <td width="26%">      <td width="26%">
67        <div align="center">Inflammation<br>        <div align="center">Inflammation<br>
68          Asthma</div>          Asthma</div>
69      </td>      </td>
70      <td width="24%">      <td width="24%">
71        <div align="center">Discovery</div>        <div align="center">Discovery</div>
72      </td>      </td>
73    </tr>    </tr>
74    <tr>    <tr>
75      <td width="19%">      <td width="19%">
76        <div align="center">PLR - 9</div>        <div align="center">PLR - 9</div>
77      </td>      </td>
78      <td width="26%">      <td width="26%">
79        <div align="center">Anti-infective</div>        <div align="center">Anti-infective</div>
80      </td>      </td>
81      <td width="24%">      <td width="24%">
82        <div align="center">Discovery</div>        <div align="center">Discovery</div>
83      </td>      </td>
84    </tr>    </tr>
85    <tr>    <tr>
86      <td width="19%">      <td width="19%">
87        <div align="center">PLR - 14</div>        <div align="center">PLR - 14</div>
88      </td>      </td>
89      <td width="26%">      <td width="26%">
90        <div align="center">Inflammation<br>        <div align="center">Inflammation<br>
91          RA, IBD</div>          RA, IBD</div>
92      </td>      </td>
93      <td width="24%">      <td width="24%">
94        <div align="center">Discovery</div>        <div align="center">Discovery</div>
95      </td>      </td>
96    </tr>    </tr>
97  </table>  </table>
98    
99    
100  <p><b>PLD-116</b></p>  <p><b>PLD-116</b></p>
101  <p>Approval from the authorities was obtained to conduct the PLD-116 Phase  <p>Approval from the authorities was obtained to conduct the PLD-116 Phase
102    I clinical study in the EU in December 2000. Prior to that, all the activities    I clinical study in the EU in December 2000. Prior to that, all the activities
103    necessary to fulfill the requirements for the clinical testing of the compound    necessary to fulfill the requirements for the clinical testing of the compound
104    had been undertaken and the pre-clinical testing completed. The PLD-116 project    had been undertaken and the pre-clinical testing completed. The PLD-116 project
105    team has been established in December 1999, to develop a novel peptide into    team was established in December 1999, to develop a novel peptide into
106    a drug for the treatment of inflammatory bowel disease. The peptide is derived    a drug for the treatment of inflammatory bowel disease. The peptide is derived
107    from a natural protein and provides a novel anti-inflammatory treatment option    from a natural protein and provides a novel anti-inflammatory treatment option
108    for inflammatory bowel disease.</p>    for inflammatory bowel disease.</p>
109  <p><b>PLD-117</b></p>  <p><b>PLD-117</b></p>
110  <p>In 1999 PLIVA signed a licensing agreement with <a  <p>In 1999 PLIVA signed a licensing agreement with <a
111  href="http://www.receptron.com">Receptron, Inc.</a>, a  href="http://www.receptron.com">Receptron, Inc.</a>, a
112  Californian based Biotech Company, and acquired exclusive worldwide rights to  Californian based Biotech Company, and acquired exclusive worldwide rights to
113  develop and market the PLD-117 peptide with TPO-like activity. The  develop and market the PLD-117 peptide with TPO-like activity. The
114  peptide PLD-117 for the treatment of thrombocytopenia, a severe complication  peptide PLD-117 for the treatment of thrombocytopenia, a severe complication
115    of cancer chemotherapy, was brought to clinical study trials in the USA in December    of cancer chemotherapy, was brought to clinical study trials in the USA in December
116    2000. The proposed treatment is based on a unique approach using peptide that    2000. The proposed treatment is based on a unique approach using peptide that
117    activates thrombopoietin (TPO) receptor.</p>    activates thrombopoietin (TPO) receptor.</p>
118  <p><b>PLD-118</b></p>  <p><b>PLD-118</b></p>
119  <p>The licensed in novel antifungal agent PLD-118 was successfully brought into  <p>The licensed in novel antifungal agent PLD-118 was successfully brought into
120    clinical development ahead of schedule in November 2000. PLD-118 has the potential    clinical development ahead of schedule in November 2000. PLD-118 has the potential
121    to be the first novel oral antifungal for the treatment of Candida infections    to be the first novel oral antifungal for the treatment of Candida infections
122    since the introduction of azoles in the 80's. After completing the preclinical    since the introduction of azoles in the 80's. After completing the preclinical
123    package and successful review of necessary documents by the ethics committee,    package and successful review of necessary documents by the ethics committee,
124  clinical studies started in the EU in November 2000.</p>  clinical studies started in the EU in November 2000.</p>
Legend:
Removed from v.1.2  
changed lines
  Added in v.1.3
  ViewVC Help
Powered by ViewVC 1.1.26